APYX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Apyx Medical Inc (APYX) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The company has strong growth potential driven by its revenue guidance increase, geographical expansion, and product approvals. Despite short-term price fluctuations, the long-term outlook is positive, supported by analyst upgrades and a favorable financial trajectory.
The technical indicators show mixed signals. The MACD is positive but contracting, RSI is neutral at 45.58, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support and resistance levels are Pivot: 3.556, R1: 3.98, S1: 3.132. The stock has a 70% chance to gain 3.96% in the next month, indicating potential for a rebound.
Analysts have upgraded the stock to 'Buy' with a price target of $6, citing strong revenue growth, product demand, and expansion opportunities.
The company raised its 2026 revenue guidance and expects to extend its cash runway through
Positive financial performance in Q4 2025, with a 34.7% YoY revenue increase.
The company reported a net loss of $1.29 million in Q4 2025, and EPS dropped by 75% YoY.
Gross margin slightly declined by 0.67% YoY.
Short-term price volatility, with a -3.81% regular market change.
In Q4 2025, Apyx Medical reported a 34.75% YoY revenue increase to $19.16 million. However, net income dropped by 71.93% YoY to -$1.29 million, and EPS decreased by 75% YoY to -0.03. The gross margin slightly declined to 62.61%. The company has $31.74 million in cash and expects to sustain operations through 2027.
Analysts are bullish on Apyx Medical. Craig-Hallum raised the price target to $6, citing strong quarterly performance and growth opportunities. BTIG upgraded the stock to 'Buy' from 'Neutral,' highlighting demand for skin tightening products, geographical expansion, and cost controls as drivers of profitability.
